Back to Journals » Drug Design, Development and Therapy » Volume 13
Research Letter
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
8,899 | Dovepress* | 7,977+ | 1,232 | 9,209 | |
PubMed Central* | 922 | 155 | 1,077 | ||
Totals | 8,899 | 1,387 | 10,286 | ||
*Since 24 January 2019 |
View citations on PubMed Central and Google Scholar